Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

@article{Brown2006AntiretroviralTA,
  title={Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review},
  author={Todd T. Brown and Roula B. Qaqish},
  journal={AIDS},
  year={2006},
  volume={20},
  pages={2165–2174}
}
Introduction:Prevalence estimates of osteopenia and osteoporosis (reduced bone mineral density; BMD) in HIV-infected patients and the role of antiretroviral therapy (ART) varies in the literature. Methods:We conducted a meta-analytical review of cross-sectional studies published in English to determine the pooled odds ratios (OR) of reduced BMD and osteoporosis in the following groups: HIV-positive versus HIV-negative; ART-treated versus ART-naive; protease inhibitor (PI)-treated versus PI… 
Osteoporosis and Vitamin D Deficiency in HIV-Positive Patients
TLDR
HIV-positive patients are at increased risk for osteoporosis and vitamin D deficiency due to disease and treatment influences on bone health and these patients should be identified and treated to prevent the morbidity and mortality associated with osteoporeosis.
Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review.
TLDR
Evaluating the frequency of bone loss, bone mineral density (BMD) and fractures in HIV-positive women taking ART or protease inhibitors (PI) found no difference between users and non-users of PI/ART.
Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors
TLDR
The prevalence of osteopenia/osteoporosis in HIV-infected and antiretroviral therapy (ART)-treated individuals was two times more compared to controls, however, evidence concerning bone loss within the first year of HIV infection and ART initiation was preliminary.
HIV and Vertebral Fractures: a Systematic Review and Metanalysis
TLDR
HIV-positive subjects had a higher risk of vertebral fractures when compared with HIV-negative subjects, according to a systematic review of randomized controlled trials, cohort studies, cross-sectional studies, and case-control studies.
Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons
TLDR
Until additional information is provided, and with available knowledge on the metabolism profiles of antiretroviral and bone ossification agents, alendronate appears to be the preferred agent to use in this population of HIV-infected patients with osteoporosis and osteopenia.
Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients.
HIV-associated osteoporosis in Ireland: prevalence and risk factors
TLDR
A significant association between decreased hip bone mineral density (BMD) and increasing age, male gender, cigarette smoking, ethnicity, intravenous drug use and lower nadir CD4 is found.
Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients
TLDR
A high prevalence of reduced BMD is confirmed, which is favoured by ritonavir-boosted PI and TDF, and should continue to be evaluated in clinical trials and cohort studies in order to demonstrate that the new drugs offer additional advantages regarding the impact on BMD.
Prevalence of osteoporosis and osteopenia in a cohort of HIV positive women with a history of treated neoplasms
TLDR
HIV patients with a history of treated cancer have a much higher prevalence of osteoporosis when compared with same-aged HIV-uninfected women with and without cancer.
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors
TLDR
This cohort-based survey of HIV-infected patients within the Aquitaine cohort showed a high prevalence of osteopenia and osteoporosis of multifactorial origin and Mechanisms and consequences of these bone disorders need to be investigated.
...
...

References

SHOWING 1-10 OF 60 REFERENCES
Relationship Between Low Bone Mineral Density and Highly Active Antiretroviral Therapy Including Protease Inhibitors in HIV-Infected Patients
TLDR
The prevalence of osteopenia in HIV-infected patients on HAART is high and loss of BMD is associated with PI therapy, low plasma albumin level, and male sex.
Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy
TLDR
Bone mineral density (BMD) was significantly lower in HIV-seropositive patients in comparison with controls in lumbar spine, proximal femur and total body, without significant differences among treatment-naive patients and either of the treatment groups.
Osteopenia in HIV-infected women prior to highly active antiretroviral therapy.
TLDR
Osteopenia in HIV-infected female subjects is commonly manifested both in lumbar spine and Ward's triangle of the hip and the decreased levels of 1,25(OH2)D may contribute to a negative calcium balance and inhibition of bone formation.
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir
TLDR
It is proposed that indinavir therapy may be associated with an increase in bone mineral density over time, and adjustment for this effect in a cross-sectional analysis abrogated the association between PI therapy and decreased lumbar spine z-score.
Abnormalities in the bone mineral metabolism in HIV-infected patients
TLDR
HIV may be an individual risk factor in bone disorders, requiring calcium and vitamin D supplementation, and a vitamin D deficiency in 86% of patients was found, with mean serum levels found to be significantly lower than those from a healthy control group.
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
  • G. Madeddu, A. Spanu, G. Madeddu
  • Medicine, Biology
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2004
TLDR
HAART could be associated with osteopenia, even osteoporosis, and it could aggravate the loss in bone mass due to HIV infection itself, as well as directly affect bone remodelling and/or may indirectly affect vitamin D metabolism.
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
TLDR
Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.
Bone mass and mineral metabolism in HIV+ postmenopausal women
TLDR
Established osteoporosis risk factors were more important in predicting BMD than factors associated with HIV infection and ART, while duration or class of antiretroviral therapy (ART), AIDS diagnosis, nadir CD4, steroid use, and vitamin D deficiency were not.
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy
TLDR
Lower total bone mineral density was associated with lower weight prior to commencing antiretroviral therapy whereas lower spinal bone mineraldensity was associated mostly with higher lactate.
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.
  • K. Mondy, K. Yarasheski, P. Tebas
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.
...
...